Receptor pharmacology

Concept

Receptor pharmacology

T-122Home BU-404Threads regulation · structure

Statement

Agonists, antagonists and binding.

Why it matters

receptor-ligand-binding establishes the biophysical equilibrium (affinity, \(K_d\), fractional occupancy) that governs how tightly a molecule binds its receptor; this result adds the second, functionally decisive layer pharmacology actually cares about — what happens once that molecule is bound. Two drugs can have identical affinity for the same receptor and yet produce completely different, even opposite, physiological effects, which is exactly the distinction between affinity and efficacy developed here. pharmacokinetics (how much drug reaches the receptor, and for how long) and dose-response (how measured response scales with dose) both presuppose the classification of agonists and antagonists built in this result, and genomic-medicine's account of inter-individual variation in drug response frequently traces back to genetic variation in the very receptors classified here.

Hypotheses

A drug's affinity (how tightly it binds the receptor, governed by receptor-ligand-binding's \(K_d\)) is conceptually and empirically separable from its efficacy (the magnitude of functional response produced once bound).Without this separation, "potent" and "effective" would collapse into one property; in reality a drug can bind extremely tightly (low \(K_d\), high affinity) yet trigger little or no functional response (low efficacy), which is precisely how antagonists are defined below. Receptor occupancy, once achieved, is translated into a graded functional response whose maximum, \(E_{\max}\), is a property of the receptor-effector system, not of the ligand's affinity alone.This is why a partial agonist can occupy \(100\%\) of receptors and still fail to reach the same \(E_{\max}\) a full agonist achieves at much lower occupancy — efficacy determines how effectively occupied receptor is converted into response, a separate question from how much receptor gets occupied at a given concentration.

Proof

\text{A full agonist binds the receptor and produces the maximal possible functional response, } E_{\max}\text{, at saturating concentration.}

A full agonist has both affinity (it binds, receptor-ligand-binding) and full efficacy (occupied receptor is converted into the largest response the receptor-effector system is capable of producing); the endogenous ligand for a receptor is, by definition, a full agonist at that receptor. A

\text{A partial agonist binds the same receptor but produces a response with } E_{\max}^{\text{partial}} < E_{\max}^{\text{full}}\text{, even at full receptor occupancy.}

A partial agonist has affinity but reduced efficacy relative to a full agonist; because its own maximum achievable response is capped below the full agonist's \(E_{\max}\), a partial agonist can act as a net agonist in the absence of full agonist (producing some response) but as a net antagonist in the presence of a full agonist (competing for and occupying receptor without contributing the full agonist's larger per-receptor response). B

\text{A competitive antagonist has affinity but zero efficacy, and competes reversibly with agonist for the same binding site.}

Because antagonist and agonist compete for the identical site, adding sufficient agonist can always outcompete a fixed concentration of competitive antagonist and still reach \(E_{\max}\); the practical effect is a parallel rightward shift of the agonist's dose-response curve (higher agonist concentration needed for a given response), with \(E_{\max}\) itself unchanged at sufficiently high agonist concentration. B

\text{A non-competitive (or irreversible) antagonist binds a distinct site, or binds irreversibly, and cannot be fully out-competed by raising agonist concentration.}

Whether by binding an allosteric site distinct from the agonist site or by binding the agonist site covalently and irreversibly, this class of antagonist effectively removes a fraction of receptor from the functional pool regardless of how much agonist is present; increasing agonist concentration cannot recover the lost response, so the dose-response curve's \(E_{\max}\) is reduced, in contrast to the competitive case of Step 3 where \(E_{\max}\) is preserved. B

\text{Potency (the concentration needed for a given, e.g. half-maximal, response) depends on both affinity and efficacy jointly, and need not track affinity alone.}

Two agonists of identical affinity (\(K_d\)) but different efficacy can require different concentrations to reach the same fraction of their own respective \(E_{\max}\), and comparing potency across agonists of different efficacy classes at all requires specifying which response level is being compared; potency and affinity are related but are not synonyms (Common errors). B

Result

\text{Full agonist: affinity + full efficacy}\ \big|\ \text{Partial agonist: affinity + partial efficacy}\ \big|\ \text{Antagonist: affinity, zero efficacy (competitive: shifts EC}_{50}\text{; non-competitive: lowers }E_{\max}\text{)}

Reading. Every ligand's pharmacological action is fully specified by two independent properties — how tightly it binds (affinity, from receptor-ligand-binding) and how effectively bound receptor is converted into functional response (efficacy) — and the four standard pharmacological categories (full agonist, partial agonist, competitive antagonist, non-competitive antagonist) are simply the different combinations these two properties can take.

Scope. This classification assumes a single receptor type mediating the measured response via the mechanism of receptor-ligand-binding; a drug can, in principle, act on multiple distinct receptor subtypes with different affinity and efficacy profiles at each, complicating a single overall classification (Discussion).

Corollaries & converses

dose-response's therapeutic window and potency comparisons between drugs are direct applications of Step 5: comparing two drugs' \(\text{EC}_{50}\) values (concentration for half-maximal response) is only a fair efficacy-independent comparison of affinity when both drugs are full agonists at the same receptor.
pharmacokinetics determines how much drug concentration actually reaches the receptor site over time, which combines with this result's dose-response relationship (concentration in, response out) to determine the drug's actual time course of effect in the body.
Converse: a dose-response curve's shape alone (rightward shift with unchanged \(E_{\max}\), versus reduced \(E_{\max}\)) is sufficient to distinguish competitive from non-competitive antagonism experimentally, without needing to know in advance where on the receptor the antagonist binds (Steps 3 and 4).

Fails without

Drop the affinity/efficacy separation (Hypotheses): without it, a partial agonist's behaviour (Step 2) is inexplicable — a molecule that binds a receptor (has affinity) yet produces a submaximal response even at full occupancy makes sense only once affinity and efficacy are recognised as two independent properties, rather than efficacy being assumed to follow automatically from binding.
Fail to distinguish competitive from non-competitive antagonism (Steps 3–4): a clinician or researcher who assumes any antagonist's effect can always be overcome simply by raising agonist dose will be surprised, and potentially administer an ineffective or unsafe escalating dose, when the antagonist present is actually non-competitive or irreversible, where \(E_{\max}\) itself has been reduced and no amount of additional agonist restores it.

Common errors

Equating affinity and efficacy, or assuming any ligand that binds a receptor must therefore be an agonist; antagonists bind with genuine, sometimes very high, affinity while having zero efficacy (Step 3, Hypotheses).
Assuming all antagonists behave identically (raising agonist dose always restores full response); this is true only for competitive antagonism (Step 3) and specifically fails for non-competitive or irreversible antagonism (Step 4), where \(E_{\max}\) is permanently reduced.
Treating potency and affinity as synonyms; potency depends jointly on affinity and efficacy (Step 5) and, for agonists of different efficacy, two drugs of identical \(K_d\) can still show different measured potency.
Assuming a partial agonist always behaves as a "weak agonist" in every context; in the presence of a full agonist, a partial agonist frequently acts functionally as a net antagonist by competing for and occupying receptor sites without contributing the full agonist's larger response (Step 2).

Discussion

The efficacy/affinity distinction and the formal receptor classification used throughout modern pharmacology owe much to R.P. Stephenson's 1956 development of the concept of "efficacy" as a property distinct from simple receptor occupancy, refining earlier, purely occupancy-based ("occupation theory") models of drug action that could not adequately explain partial agonism.

Real drugs frequently act on more than one receptor subtype, each with its own affinity and efficacy profile, so a compound can behave as a full agonist at one receptor subtype and a partial agonist, or even an antagonist, at a related subtype in the same tissue or a different one — a major source of both a drug's intended therapeutic breadth and its off-target side effects, and a direct complication of this Result's Scope note that the classification strictly applies per receptor type, not to a drug as a single, unconditional label.

Common misconception: that a "stronger" drug (in the colloquial sense) is simply one with higher affinity for its receptor. Clinical effectiveness depends on the combination of affinity, efficacy, and pharmacokinetic exposure (pharmacokinetics) together; a high-affinity partial agonist can produce a smaller maximal effect than a lower-affinity full agonist, despite binding more tightly.

Worked examples

\text{Full agonist alone reaches } E_{\max}=100. \text{ Adding a fixed concentration of a competitive antagonist requires a }10\times\text{ higher agonist concentration for the same response, but } E_{\max}\text{ is still eventually reached.}

This is the diagnostic signature of competitive antagonism (Step 3): a parallel rightward shift of the dose-response curve (more agonist needed at every response level) with the maximum response \(E_{\max}\) ultimately unchanged once agonist concentration is raised enough to out-compete the fixed antagonist concentration. A

\text{Same full agonist, same nominal antagonist concentration, but now no amount of added agonist restores } E_{\max}=100\text{; the ceiling response is reduced to }60.

Because raising agonist concentration cannot recover the lost maximal response, this is the diagnostic signature of non-competitive (or irreversible) antagonism (Step 4): a portion of the receptor pool has been functionally removed from availability regardless of agonist concentration, permanently lowering the ceiling response rather than merely shifting the curve rightward. A

\text{Rightward shift, unchanged }E_{\max}\Rightarrow\text{competitive}\ \big|\ \text{Reduced }E_{\max}\Rightarrow\text{non-competitive/irreversible}

Reading. The shape of the shift in a dose-response curve, not just the presence of a shift, is what distinguishes the two antagonist classes experimentally.

Scope. This diagnostic applies whenever a clean dose-response curve for the agonist alone, and in the presence of a fixed antagonist concentration, can both be measured under comparable conditions.

Problems

A new compound is found to bind a receptor with very high affinity (\(K_d\) far lower than the endogenous full agonist's), but produces no measurable functional response on its own, and blocks the endogenous agonist's effect when both are present together. Classify this compound using the Result.
Solution
This is a competitive antagonist (or possibly non-competitive, depending on whether raising endogenous agonist concentration can restore full response, which is not stated). It has affinity (binds tightly, evidenced by the low \(K_d\)) but zero efficacy (no response on its own, Step 3's or Step 4's defining feature), and blocks the full agonist's effect, consistent with competing for the same functional outcome. High affinity alone (Common errors, first bullet) does not make it an agonist; the absence of any response despite binding is what identifies it as having zero efficacy.
A drug produces \(70\%\) of the maximal response achievable by the endogenous full agonist, even when given at a saturating (fully receptor-occupying) concentration. Classify the drug and explain, using Step 2, what its effect will be when co-administered with a saturating concentration of the full endogenous agonist.
Solution
This is a partial agonist: full receptor occupancy is achieved, yet the ceiling response (\(70\%\) of \(E_{\max}\)) is below the full agonist's own \(E_{\max}\), indicating reduced efficacy rather than reduced affinity or occupancy. Co-administered with a saturating concentration of full agonist, the partial agonist will compete for and occupy some receptor sites, each of which then produces less response than if the full agonist alone had occupied that site; the net measured response will fall below the full agonist's own \(E_{\max}\), so the partial agonist acts functionally as a net antagonist in this specific context (Step 2).
Explain, using Step 5, why it is not valid to conclude that Drug X has higher affinity for a receptor than Drug Y simply because Drug X requires a lower concentration to produce a given percentage of its own maximal response than Drug Y requires to produce the corresponding percentage of its own maximal response, if Drug Y is known to be a partial agonist and Drug X a full agonist.
Solution
Potency (the concentration needed for a given response) depends on both affinity and efficacy jointly (Step 5), not on affinity alone. If Drug Y is a partial agonist, its lower efficacy already tends to require a different relationship between occupancy and response than a full agonist's; comparing "percentage of own maximal response" across drugs of different efficacy classes conflates affinity differences with efficacy differences, and a valid comparison of affinity alone would require directly comparing each drug's \(K_d\) (receptor-ligand-binding), not their functional potency expressed relative to their own, different \(E_{\max}\) values.